View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDeinove 将来の成長Future 基準チェック /26主要情報77.4%収益成長率74.80%EPS成長率Chemicals 収益成長11.2%収益成長率97.8%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日31 Oct 2022今後の成長に関する最新情報Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.Price Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.すべての更新を表示Recent updatesBreakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Oct 08First half 2022 earnings releasedFirst half 2022 results: Net loss: €3.56m (loss widened 13% from 1H 2021). Revenue is forecast to grow 201% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Chemicals industry in France.お知らせ • May 20Deinove SA, Annual General Meeting, May 30, 2022Deinove SA, Annual General Meeting, May 30, 2022, at 15:00 Central European Standard Time. Location: 48 rue Cambon Paris FrancePrice Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.Reported Earnings • Apr 14Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Net loss: €6.96m (loss narrowed 4.7% from FY 2020). Revenue exceeded analyst estimates by 19%. Over the next year, revenue is expected to shrink by 33% compared to a 22% growth forecast for the industry in France.お知らせ • Apr 08Deinove SA Announces the Extension of Its Clinical Trial to CanadaDeinove SA announced the extension of its clinical trial to Canada, approved by the Canadian Health authority, with the opening of 5 new sites, complementing those already opened in the United States. This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections. The second part of the study will be conducted in an open-label manner. Thus, all 40 patients who will be included in the trial will receive DNV3837. As a reminder, the second part of the trial has been optimized with a reduction in the dose and duration of intravenous administration to 6 hours per day during the 10-day treatment period. This modification simplifies the management of the trial for the investigating physicians and their teams. More than 40% of hospitalized patients with Clostridioides difficile infection (CDI) have been classified as severe disease associated with higher morbidity and mortality1. The Centers for Disease Control and Prevention (CDC) identifies CDI as one of the leading causes of hospital-acquired infections, ahead of even MRSA2 infections. In the United States, it is estimated that CDI causes nearly half a million disease cases each year, and approximately 29,300 deaths3. This condition is not limited to the United States and recent studies4 show that the incidence of this type of infection is greatly underestimated in other parts of the world, such as Europe and Asia. To date, there is no proven therapeutic solution for CDI patients with severe vomiting, ileus and toxic megacolon. The oral route being compromised, the available treatments, which are mostly oral, have difficulty reaching the intestine because of the patient's pathological condition (reduced gastrointestinal motility, intubation, intestinal perforation, etc.), and the few antibiotics that could be administered intravenously do not cross the gastrointestinal barrier and therefore do not reach the infection site. DNV3837 – a prodrug5 of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active first-line treatment targeting C. diff. It has demonstrated significant activity and superiority to reference treatments against isolates of C. diff., regardless of their virulence (including the hyper virulent BI/NAP1/027 strain). DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. Several Phase I trials (on approximately a hundred healthy volunteers) have shown a high concentration of the antibiotic in stools, a strong marker of its presence in the intestine. It has also demonstrated its ability to eliminate Clostridioides bacteria without affecting the gut microbiota. FDA granted the DNV3837 drug with Qualified Infectious Disease Product (QIDP) designation and Fast Track status.お知らせ • Jan 07Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile InfectionsDEINOVE announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI). The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial. The experience acquired during this first part of the study has made it possible to improve the trial protocol, with a reduction in dose by a factor of 4 and a reduction in the duration of administration by a factor of 2, reducing the intravenous treatment from 12 to 6 hours per day. This improvement simplifies the management of the trial for the investigating physicians and their teams. The second part of the study will be conducted in an “open-label” manner, as DNV3837 is administered intravenously, while the standards of care are administered orally. Thus, all patients included in the trial (40 in total) will receive DNV3837. To improve patients inclusion in the trial, it was decided to rapidly open new centers in addition to those active in the United States.Reported Earnings • Oct 03First half 2021 earnings releasedFirst half 2021 results: Net loss: €3.15m (loss narrowed 32% from 1H 2020).Reported Earnings • Mar 27Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €836.0k (up 49% from FY 2019). Net loss: €7.30m (loss narrowed 29% from FY 2019).お知らせ • Jan 22Deinove SA Appoints Hervé Ansanay as DirectorDeinove SA announces the strengthening of its Business Development team with the appointment of Hervé ANSANAY as Director and Corentin. The recruitment will intensify the implementation of profitable strategic partnerships and the access to non-dilutive financing, to support the development of antimicrobial therapeutic solutions. Hervé ANSANAY brings 20 years experience in accompanying innovative companies and in technology transfer. He was previously Technology Transfer and Business Development Director of the SATT AxLR of Montpellier where he also held the position of Chief Operating Officer.Is New 90 Day High Low • Jan 05New 90-day high: €0.91The company is up 50% from its price of €0.61 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.Is New 90 Day High Low • Nov 26New 90-day high: €0.73The company is up 7.0% from its price of €0.68 on 28 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.58 per share.お知らせ • Nov 20Deinove SA Signs an Evaluation and Technology Development License with DSMDeinove SA announced the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living. Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.Is New 90 Day High Low • Oct 26New 90-day low: €0.54The company is down 30% from its price of €0.77 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share.Reported Earnings • Oct 15First half earnings releasedOver the last 12 months the company has reported total losses of €9.52m, with losses narrowing by 8.2% from the prior year.業績と収益の成長予測ENXTPA:ALDEI - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202421233112/31/202316-3-2-2112/31/20221-8-7-716/30/20220-7-7-7N/A3/31/20220-7-7-6N/A12/31/20211-7-6-6N/A9/30/20211-6N/AN/AN/A6/30/20211-6-6-6N/A3/31/20211-7-6-5N/A12/31/20201-7-5-5N/A9/30/20201-8N/AN/AN/A6/30/20201-10-4-4N/A3/31/20201-10-5-5N/A12/31/20191-10-7-6N/A9/30/20190-10N/AN/AN/A6/30/20190-10-10-9N/A3/31/20191-10-11-10N/A12/31/20181-9-11-10N/A9/30/20181-8N/AN/AN/A6/30/20181-8-9-7N/A3/31/20180-8-8-7N/A12/31/20170-7-8-7N/A9/30/20170-7N/AN/AN/A6/30/20171-6-8-7N/A3/31/20171-6-7-6N/A12/31/20161-6-6-5N/A9/30/20161-6N/AN/AN/A6/30/20161-7-5-5N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ALDEI今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: ALDEI今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: ALDEI今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: ALDEIの収益 ( 97.8% ) French市場 ( 5.6% ) よりも速いペースで成長すると予測されています。高い収益成長: ALDEIの収益 ( 97.8% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ALDEIの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/04/08 15:37終値2023/01/10 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Deinove SA 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Jonas PeciulisEdison Investment ResearchArnaud GuérinPortzamparc BNP ParibasPierre VauriceTPICAP Midcap
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
Price Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.
Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.
Breakeven Date Change • Nov 16Forecast to breakeven in 2024The analyst covering Deinove expects the company to break even for the first time. New forecast suggests losses will reduce by 33% per year to 2023. The company is expected to make a profit of €1.70m in 2024. Average annual earnings growth of 77% is required to achieve expected profit on schedule.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. 3 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Oct 08First half 2022 earnings releasedFirst half 2022 results: Net loss: €3.56m (loss widened 13% from 1H 2021). Revenue is forecast to grow 201% p.a. on average during the next 2 years, compared to a 5.5% growth forecast for the Chemicals industry in France.
お知らせ • May 20Deinove SA, Annual General Meeting, May 30, 2022Deinove SA, Annual General Meeting, May 30, 2022, at 15:00 Central European Standard Time. Location: 48 rue Cambon Paris France
Price Target Changed • Apr 27Price target decreased to €1.00Down from €1.20, the current price target is provided by 1 analyst. New target price is 291% above last closing price of €0.26. Stock is down 62% over the past year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 8 experienced directors. 4 highly experienced directors. Chairman of the Board Charles Woler was the last director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Apr 15Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €600.0k to €400.0k. EPS estimate increased from -€0.29 to -€0.27 per share. Chemicals industry in France expected to see average net income decline 46% next year. Consensus price target of €1.00 unchanged from last update. Share price fell 3.9% to €0.29 over the past week.
Reported Earnings • Apr 14Full year 2021 earnings: Revenues exceed analyst expectationsFull year 2021 results: Net loss: €6.96m (loss narrowed 4.7% from FY 2020). Revenue exceeded analyst estimates by 19%. Over the next year, revenue is expected to shrink by 33% compared to a 22% growth forecast for the industry in France.
お知らせ • Apr 08Deinove SA Announces the Extension of Its Clinical Trial to CanadaDeinove SA announced the extension of its clinical trial to Canada, approved by the Canadian Health authority, with the opening of 5 new sites, complementing those already opened in the United States. This second country will accelerate patient enrollment in this Phase II clinical trial of DNV3837 in Clostridioides difficile infections. The second part of the study will be conducted in an open-label manner. Thus, all 40 patients who will be included in the trial will receive DNV3837. As a reminder, the second part of the trial has been optimized with a reduction in the dose and duration of intravenous administration to 6 hours per day during the 10-day treatment period. This modification simplifies the management of the trial for the investigating physicians and their teams. More than 40% of hospitalized patients with Clostridioides difficile infection (CDI) have been classified as severe disease associated with higher morbidity and mortality1. The Centers for Disease Control and Prevention (CDC) identifies CDI as one of the leading causes of hospital-acquired infections, ahead of even MRSA2 infections. In the United States, it is estimated that CDI causes nearly half a million disease cases each year, and approximately 29,300 deaths3. This condition is not limited to the United States and recent studies4 show that the incidence of this type of infection is greatly underestimated in other parts of the world, such as Europe and Asia. To date, there is no proven therapeutic solution for CDI patients with severe vomiting, ileus and toxic megacolon. The oral route being compromised, the available treatments, which are mostly oral, have difficulty reaching the intestine because of the patient's pathological condition (reduced gastrointestinal motility, intubation, intestinal perforation, etc.), and the few antibiotics that could be administered intravenously do not cross the gastrointestinal barrier and therefore do not reach the infection site. DNV3837 – a prodrug5 of the DNV3681 molecule (also known as MCB3681) – is a narrow-spectrum, hybrid oxazolidinone-quinolone synthetic antibiotic targeting only Gram-positive bacteria. It is developed as a highly active first-line treatment targeting C. diff. It has demonstrated significant activity and superiority to reference treatments against isolates of C. diff., regardless of their virulence (including the hyper virulent BI/NAP1/027 strain). DNV3837 is an intravenous antibiotic that, when converted to its active form DNV3681, crosses the gastrointestinal barrier and accumulates in the intestinal lumen, allowing it to precisely target the infection site. Several Phase I trials (on approximately a hundred healthy volunteers) have shown a high concentration of the antibiotic in stools, a strong marker of its presence in the intestine. It has also demonstrated its ability to eliminate Clostridioides bacteria without affecting the gut microbiota. FDA granted the DNV3837 drug with Qualified Infectious Disease Product (QIDP) designation and Fast Track status.
お知らせ • Jan 07Deinove SA Announces A Favorable Opinion from the DSMBfor the Continuation of the Phase II Clinical Trial of DNV3837 in Clostridioides Difficile InfectionsDEINOVE announced that the independent Data Safety Monitoring Board (DSMB) has completed its review of the safety data from the first part of the Phase II clinical trial of DNV3837 in the treatment of Clostridioides difficile infection (CDI). The DSMB considered that the benefit/risk balance of antibiotic therapy with DNV3837 was in favor of continuing the recruitment in this trial. The experience acquired during this first part of the study has made it possible to improve the trial protocol, with a reduction in dose by a factor of 4 and a reduction in the duration of administration by a factor of 2, reducing the intravenous treatment from 12 to 6 hours per day. This improvement simplifies the management of the trial for the investigating physicians and their teams. The second part of the study will be conducted in an “open-label” manner, as DNV3837 is administered intravenously, while the standards of care are administered orally. Thus, all patients included in the trial (40 in total) will receive DNV3837. To improve patients inclusion in the trial, it was decided to rapidly open new centers in addition to those active in the United States.
Reported Earnings • Oct 03First half 2021 earnings releasedFirst half 2021 results: Net loss: €3.15m (loss narrowed 32% from 1H 2020).
Reported Earnings • Mar 27Full year 2020 earnings releasedThe company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: €836.0k (up 49% from FY 2019). Net loss: €7.30m (loss narrowed 29% from FY 2019).
お知らせ • Jan 22Deinove SA Appoints Hervé Ansanay as DirectorDeinove SA announces the strengthening of its Business Development team with the appointment of Hervé ANSANAY as Director and Corentin. The recruitment will intensify the implementation of profitable strategic partnerships and the access to non-dilutive financing, to support the development of antimicrobial therapeutic solutions. Hervé ANSANAY brings 20 years experience in accompanying innovative companies and in technology transfer. He was previously Technology Transfer and Business Development Director of the SATT AxLR of Montpellier where he also held the position of Chief Operating Officer.
Is New 90 Day High Low • Jan 05New 90-day high: €0.91The company is up 50% from its price of €0.61 on 07 October 2020. The French market is up 14% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Nov 26New 90-day high: €0.73The company is up 7.0% from its price of €0.68 on 28 August 2020. The French market is up 11% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Chemicals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.58 per share.
お知らせ • Nov 20Deinove SA Signs an Evaluation and Technology Development License with DSMDeinove SA announced the signing of an evaluation and technology development license with DSM, a global science-based company in Nutrition, Health and Sustainable Living. Under the agreement, DSM will evaluate the potential of a microbial strain from DEINOVE as a feed additive; selected and characterized during the Color-2B program. The evaluation and technology development program is undertaken and supervised by DSM. For the exclusive purpose of the performance of the collaboration activities, DSM is granted a temporary exclusive license to use DEINOVE’s proprietary strain, as well as the background intellectual property related to the strain and required for the collaboration activities. In consideration of these provisions, DEINOVE will receive a upfront and milestone payments during program execution (undisclosed amount). Upon DSM’s decision that the collaboration activities are successful, DEINOVE and DSM will pursue negotiations for a commercial license agreement.
Is New 90 Day High Low • Oct 26New 90-day low: €0.54The company is down 30% from its price of €0.77 on 28 July 2020. The French market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.07 per share.
Reported Earnings • Oct 15First half earnings releasedOver the last 12 months the company has reported total losses of €9.52m, with losses narrowing by 8.2% from the prior year.